# **CLINICAL TRIALS** FOR **RARE DISEASES** IN SPAIN 2022 \*

asociación española de laboratorios de medicamentos huérfanos y ultrahuérfanos

Clinical trials are research mechanisms used to determine the safety and efficacy of medicines

No. of clinical trials (2021 2022)

923

233

2022

Clinical trials for rare diseases

996

225

2021

Total clinical trials


Currently, 95% of rare diseases **have no diagnostic tool or treatment** 

25%


3%

25% of clinical trials authorised in Spain in 2022 are studying treatments for rare diseases


95%



#### No. of participants in clinical trials (2021-2022)



#### AUTHORISED CLINICAL TRIALS FOR **RARE DISEASES** BY REGION AND **CENTER** IN **2022**\*\*



**Catalonia, the Community of Madrid, Valencian Community** and **Andalusia** are the regions with highest participation in clinical trials for rare diseases

# 164 centres hosted clinical trials for rare diseases:

39 in the Community of Madrid, 37 in Catalonia and 22 in Andalusia

233

trials

in 2022

Hospitals with the highest no. of clinical trials on rare diseases

- **101** Vall d'Hebron University Hospital (Barcelona)
- **70** La Fe University and Polytechnic Hospital (Valencia)
- 66 Clínic Hospital (Barcelona)


### CLINICAL TRIALS FOR **RARE DISEASES** BY **THERAPEUTIC AREA**

- 57 Oncology
- 28 Nervous System
- 23 Haematology
- **23** Immune System

The research area on rare diseases with the fastest growth has been **genetic phenomena**, **increasing from 2 trials in 2021 to 10 trials in 2022** 


# PROMOTERS OF CLINICAL TRIALS


**226 out of 233 authorised trials** in Spain in 2022 for rare diseases, were driven by **commercial promoters** 



Clinical trials in rare diseases by commercial promoters

## CLINICAL TRIALS FOR **RARE DISEASES** IN **SPAIN** 2018-2022






Percentage of variation by therapeutic areas (2018 vs. 2022)

The research areas on rare diseases with the **highest growth** between 2018 and 2022 have been **immune system and nervous system diseases** (61% and 50% growth respectively)

#### CLINICAL TRIALS FOR RARE DISEASES BY AELMHU PARTNERS 2018-2022



\*Clinical trials authorized during 2022 Source <u>Registro Español de Estudios Clínicos (REec AEMPS)</u> Information analysed by BioInnova Consulting \*\*Most of analyzed trials have been multicenter clinical trials. Each individual trial has been counted in several regions

